MUMBAI, India, April 20 -- Intellectual Property India has published a patent application (202637044396 A) filed by Hangzhou Adcoris Biopharma Co. Ltd., Zhejiang, China, on April 7, for 'exatecan hydroxylamine derivative and use thereof.'
Inventor(s) include Miao, Zhenwei; Huang, Yunsheng; and Li, Yaowu.
The application for the patent was published on April 17, under issue no. 16/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a method for preparing a series of exatecan derivatives containing a hydroxylamine structure substitution and pharmaceutically acceptable salts thereof, and the use thereof in the field of anti-tumor. These exatecan derivatives not only have a good activity of inhibiting the growth of tumor cells, but also have a good capability of permeating cell membranes or bystander effect, and can be used as monotherapy, combination therapy, or as toxin components of ADC for the treatment of tumors."
The patent application was internationally filed on Sept. 14, 2024, under International application No.PCT/CN2024/119146.
Disclaimer: Curated by HT Syndication.
